These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36713577)

  • 1. Suppression of head and neck cancer cell survival and cisplatin resistance by GRP78 small molecule inhibitor YUM70.
    Yamamoto V; Wang B; Lee AS
    Front Oncol; 2022; 12():1044699. PubMed ID: 36713577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors.
    Yamamoto V; Ha DP; Liu Z; Huang M; Samanta S; Neamati N; Lee AS
    Neoplasia; 2024 Sep; 55():101020. PubMed ID: 38991376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer.
    Samanta S; Yang S; Debnath B; Xue D; Kuang Y; Ramkumar K; Lee AS; Ljungman M; Neamati N
    Cancer Res; 2021 Apr; 81(7):1883-1895. PubMed ID: 33531374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GRP78 Inhibitor YUM70 Suppresses SARS-CoV-2 Viral Entry, Spike Protein Production and Ameliorates Lung Damage.
    Ha DP; Shin WJ; Hernandez JC; Neamati N; Dubeau L; Machida K; Lee AS
    Viruses; 2023 May; 15(5):. PubMed ID: 37243204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
    Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
    Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
    Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
    Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion.
    Sarnella A; Ferrara Y; Auletta L; Albanese S; Cerchia L; Alterio V; De Simone G; Supuran CT; Zannetti A
    J Exp Clin Cancer Res; 2022 Apr; 41(1):122. PubMed ID: 35365193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
    J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentagalloyl Glucose and Cisplatin Combination Treatment Exhibits a Synergistic Anticancer Effect in 2D and 3D Models of Head and Neck Carcinoma.
    Kantapan J; Intachai N; Khamto N; Meepowpan P; Sangthong P; Wantanajittikul K; Dechsupa N; Chitapanarux I
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-Epitaxol induces apoptosis in cisplatin-resistant head and neck squamous cell carcinoma via suppression of AKT and MAPK signalling.
    Yang HJ; Velmurugan BK; Chen MK; Lin CC; Lo YS; Chuang YC; Ho HY; Hsieh MJ; Ko JL
    J Cell Mol Med; 2022 Dec; 26(23):5807-5819. PubMed ID: 36308422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The two-faced role of RNA methyltransferase METTL3 on cellular response to cisplatin in head and neck squamous cell carcinoma
    Ostrowska K; Rawłuszko-Wieczorek AA; Ostapowicz J; Suchorska WM; Golusiński W
    Front Oncol; 2024; 14():1402126. PubMed ID: 38966069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATR inhibition sensitizes HPV
    Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
    Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations.
    Ha DP; Huang B; Wang H; Rangel DF; Van Krieken R; Liu Z; Samanta S; Neamati N; Lee AS
    Neoplasia; 2022 Nov; 33():100837. PubMed ID: 36162331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
    Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
    BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
    Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
    Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure to Secondhand Smoke Extract Increases Cisplatin Resistance in Head and Neck Cancer Cells.
    Sadhasivam B; Manyanga J; Ganapathy V; Acharya P; Bouharati C; Chinnaiyan M; Mehta T; Mathews B; Castles S; Rubenstein DA; Tackett AP; Zhao YD; Ramachandran I; Queimado L
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.